ArticleBMC cancer2024

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation.

Yanjuan Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.